



## Financial Tear Sheet

### Corporate Profile

BeiGene, Ltd. (“BeiGene”) is a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer.

BeiGene has a broad portfolio consisting of six internally-developed, clinical-stage, drug candidates, including three late-stage clinical drug candidates, zanubrutinib (BTK inhibitor), tislelizumab (PD-1 antibody), and pamiparib (PARP inhibitor). BeiGene has also in-licensed five drugs and drug candidates, including three marketed drugs in China ABRAXANE®, REVLIMID® and VIDAZA® under an exclusive license from Celgene Corporation, and two clinical-stage drug candidates with development and commercialization rights in China and other selected countries in the Asia-Pacific region.

BeiGene was established in Beijing in 2010 and listed on the U.S. NASDAQ Global Select Market in February 2016. As of July 2018, the Company had a global team of over 1,300 employees. BeiGene operates as a fully-integrated global biotechnology company with broad capabilities, both in China and globally, spanning research, clinical development, manufacturing and commercialization.

### Primary IR Contact

Investor Relations

E-mail:

[ir@beigene.com](mailto:ir@beigene.com)

### Stock Information

BGNE (American Depositary Shares)

Exchange	NASDAQ GS (US Dollar)
Price	<b>\$132.22</b>

Change (%) ▼ 2.46 (1.83%)

---

Volume 279,453

---

52 Week High \$220.10

---

52 Week Low \$105.19

---

Market Cap \$104,021,873,621

---

Rolling EPS -9.61

---

PE Ratio 0

---

Shares Outstanding 772,363,184

---

Data as of 02/15/19 4:00 p.m. ET

## Press Releases

February 13, 2019

[BeiGene to Hold Fourth Quarter and Full Year 2018 Financial Results Conference Call on February 27, 2019 and Host Investor Event in Hong Kong](#)

---

February 7, 2019

[BeiGene to Present at the Guggenheim Healthcare Talks Idea Forum – Oncology Day](#)

---

January 14, 2019

[BeiGene Receives U.S. FDA Breakthrough Therapy Designation for Zanubrutinib in Mantle Cell Lymphoma](#)

---

## SEC Filings

Filing Date	Form
02/13/19	<a href="#">SC 13G/A</a>
02/12/19	<a href="#">SC 13G</a>
02/12/19	<a href="#">SC 13G/A</a>
01/23/19	<a href="#">8-K</a>

---

## Upcoming Events

Date	Title
27 Feb 2019 6:00 p.m. ET	<a href="#">Q4 2018 BeiGene, Ltd. Earnings Conference Call</a>
28 Feb 2019 2:30 p.m. HKT	<a href="#">Hong Kong Investor Event</a> Location: Location: Island Shangri-La, Hong Kong, Level 5, Ballroom A

---

## Corporate Governance

### Governance Documents

-  [Code of Business Conduct and Ethics](#)
  -  [Corporate Governance Guidelines](#)
  -  [Securityholder Communication Policy](#)
- 

### Committee Charters

-  [Audit Committee](#)
  -  [Compensation Committee](#)
  -  [Nominating and Corporate Governance Committee](#)
- 

Data provided by Nasdaq. Minimum 15 minutes delayed.

© 2016 BeiGene. All Rights Reserved.